Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Mwangi Wa Mutahi

Neng-Yang Shih

Robert G Aslanian

Stuart B Rosenblum

Kevin D McCormick

Daniel M Solomon

John J Baldwin

Ge Li

John J Piwinski

Pauline C Ting

Qingbei Zeng

Henry A Vaccaro

Jianhua Cao

Ronald L Wolin

Tom G Wing

Disclosed are novel compounds of the formula  Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a Hreceptor antagonist.

Piperidine compounds

Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H. receptor antagonist.

The present invention discloses novel substituted imidazole compounds which have H receptor antagonist or dual histamine-H and H receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.

Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists

The present invention discloses novel substituted imidazole compounds which have either or dual histamine-H and H receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.

Growing community of inventors

Edison, NJ, United States of America

Mwangi Wa Mutahi